Publication:
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

Simple item page
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsKorkmaz, T.; Seber, S.; Kefeli, U.; Sari, E.; Canhoroz, M.; Oven, B.; Yildirim, E.; Yasar, N.; Aydin, D.; Balvan, O.; Sener, N.; Yuksel, S.; Mert, A.; Polat, O.; Yumuk, F.; Kanat, O.; Gumus, M.; Turhal, N. S.
dc.date.accessioned2022-03-12T18:10:57Z
dc.date.available2022-03-12T18:10:57Z
dc.date.issued2013
dc.description.abstractSmall cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
dc.identifier.doi10.1007/s12094-012-0960-6
dc.identifier.eissn1699-3055
dc.identifier.issn1699-048X
dc.identifier.pubmed23143955
dc.identifier.urihttps://hdl.handle.net/11424/231415
dc.identifier.wosWOS:000321112900005
dc.language.isoeng
dc.publisherSPRINGER INTERNATIONAL PUBLISHING AG
dc.relation.ispartofCLINICAL & TRANSLATIONAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPlatinum sensitive disease
dc.subjectPlatinum refracter disease
dc.subjectSecond-line chemotherapy
dc.subjectSmall cell lung cancer
dc.subjectPHASE-II
dc.subjectTOPOTECAN
dc.subjectCHEMOTHERAPY
dc.subjectETOPOSIDE
dc.subjectCISPLATIN
dc.subjectPROGRESS
dc.subjectTHERAPY
dc.subjectTRIAL
dc.subjectCARE
dc.titleComparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
dc.typearticle
dspace.entity.typePublication
local.avesis.id5d56018f-2428-46e7-a0ff-b0fadf7d8cff
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages6
oaire.citation.endPage540
oaire.citation.issue7
oaire.citation.startPage535
oaire.citation.titleCLINICAL & TRANSLATIONAL ONCOLOGY
oaire.citation.volume15
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscovery4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa

Files

Collections

Research Outputs